Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Iain L. Lamont"'
Autor:
Karl A. Glen, Iain L. Lamont
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 10 (2024)
ABSTRACT Pseudomonas aeruginosa is a highly problematic opportunistic pathogen that causes a range of different infections. Infections are commonly treated with β-lactam antibiotics, including cephalosporins, monobactams, penicillins, and carbapenem
Externí odkaz:
https://doaj.org/article/5ef5b9c8833d4f31b0751f9df06db4b0
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 14 (2024)
Antibiotic drug combination therapy is critical for the successful treatment of infections caused by multidrug resistant pathogens. We investigated the efficacy of β-lactam and β-lactam/β-lactamase inhibitor combinations with other antibiotics, ag
Externí odkaz:
https://doaj.org/article/889eb318d7c54984b634a5626c15eed3
Autor:
Xiaoya Wei, Jiacong Gao, Congjuan Xu, Xiaolei Pan, Yongxin Jin, Fang Bai, Zhihui Cheng, Iain L. Lamont, Daniel Pletzer, Weihui Wu
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 5 (2023)
ABSTRACT Pseudomonas aeruginosa is a ubiquitous opportunistic pathogen that can cause a variety of acute and chronic infections. The bacterium is highly resistant to numerous antibiotics. Murepavadin is a peptidomimetic antibiotic that blocks the fun
Externí odkaz:
https://doaj.org/article/31c948b662b64e539d820237b2847c64
Autor:
Sarah Harrison, Michael G. Baker, Jackie Benschop, Russell G. Death, Nigel P. French, Garth Harmsworth, Robin J. Lake, Iain L. Lamont, Patricia C. Priest, James E. Ussher, David R. Murdoch
Publikováno v:
One Health Outlook, Vol 2, Iss 1, Pp 1-6 (2020)
Abstract There is increased recognition that complex health challenges at the human-animal-environmental interface require a transdisciplinary, “whole-of-society” approach. This philosophy is particularly pertinent in Aotearoa-New Zealand because
Externí odkaz:
https://doaj.org/article/784e5593186a4c279d994159d5d1407f
Autor:
Aswin Thacharodi, Iain L. Lamont
Publikováno v:
Antibiotics, Vol 12, Iss 1, p 152 (2023)
Pseudomonas aeruginosa causes a wide range of acute and chronic infections. Aminoglycosides are a cornerstone of treatment, but isolates are often resistant. The purpose of this research was to better understand the genetic basis of aminoglycoside re
Externí odkaz:
https://doaj.org/article/c909926517fe48aabf58551fb4e773aa
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Pseudomonas aeruginosa chronically infects in the lungs of people with cystic fibrosis and other forms of lung disease. Infections are treated with antibiotics, but over time, the bacteria acquire mutations that reduce their antibiotic susceptibility
Externí odkaz:
https://doaj.org/article/e234bd25bc3647268937a4d1ec8f0f3e
Autor:
Aswin Thacharodi, Iain L. Lamont
Publikováno v:
Antibiotics, Vol 11, Iss 7, p 884 (2022)
Aminoglycosides are widely used to treat infections of Pseudomonas aeruginosa. Genes encoding aminoglycoside-modifying enzymes (AMEs), acquired by horizontal gene transfer, are commonly associated with aminoglycoside resistance, but their effects hav
Externí odkaz:
https://doaj.org/article/4776d0fe9fce4d669fba67094c6833a7
Autor:
Karl A. Glen, Iain L. Lamont
Publikováno v:
Pathogens, Vol 10, Iss 12, p 1638 (2021)
Pseudomonas aeruginosa is a major opportunistic pathogen, causing a wide range of acute and chronic infections. β-lactam antibiotics including penicillins, carbapenems, monobactams, and cephalosporins play a key role in the treatment of P. aeruginos
Externí odkaz:
https://doaj.org/article/d3609037237a4de096375a9ca41f3c8f
Autor:
Jessica M. Thomson, Iain L. Lamont
Publikováno v:
Frontiers in Microbiology, Vol 10 (2019)
The rapid increase in antibiotic-resistant bacteria has emphasized the urgent need to identify new treatments for bacterial infections. One attractive approach, reducing the need for expensive and time-consuming clinical trials, is to repurpose exist
Externí odkaz:
https://doaj.org/article/461d1555ba3c4607808ab3896cd8ec1e
Publikováno v:
Frontiers in Microbiology, Vol 8 (2017)
Extracytoplasmic function (ECF) sigma factors control expression of large numbers of genes in bacteria. Most ECF sigma factors are inhibited by antisigma proteins, with inhibition being relieved by environmental signals that lead to inactivation of t
Externí odkaz:
https://doaj.org/article/5d428db494444ab89cb23854514b93ba